New medical insurance reimbursement policy for bosutinib

Since Bosutinib (Bosutinib)’s original drug is not on the market in China, it cannot be included in medical insurance. Patients can only choose overseas channels to learn about the relevant prices of the drug at their own expense. Once bosutinib is launched in China and included in medical insurance, if certain conditions are met, such as formally participating in medical insurance and paying fees as required, medical conditions meeting the indications for use, and obtaining prescriptions through formal channels, etc., it can enjoy medical insurance subsidies and reduce drug purchase costs.

Bosutinib joins approved medical devicesTKIs and is an orally active dual Src/Abl TKI, which has demonstrated activity as first-line therapy in patients with chronic phase (CP) chronic myelogenous leukemia (CML) and in patients with imatinib and nilotinib and span>/Or clinical benefit as second-line treatment for patients with CP-CML who are resistant or intolerant to imatinib after failure of dasatinib treatment and as third-line/fourth-line treatment for patients with CP or advanced (AP or BP) leukemia The adverse events (AEs) of bosutinib are different from otherTKIs. Diarrhea is the major toxicity associated with bosutinib treatment; other common non-hematologic adverse events include rash and elevated liver enzymes. Cardiac events, fluid retention, and electrolyte abnormalities occur rarely.

The original drugs currently sold overseas include Turkish version and European version. The Turkish version specificationsThe price of each box of 500mg*28 may be more than 2,000 yuan, and the price of the European version may be more than 30,000 yuan (the price may fluctuate due to the exchange rate). There are also bosutinib generic drugs produced overseas in other countries. Their pharmaceutical ingredients are basically the same as those of the original drug. The price of 500mg*30 per box may be more than 2,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.